PAVmed Depreciation & Amortization Growth & History (PAVM)
PAVmed's depreciation and amortization was $105,000 for fiscal 2025.
View full PAVmed company overviewPAVmed annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $105,000 | −$1.1M | −91.24% |
| 2024 | 2024-12-31 | $1.2M | −$1.7M | −59.14% |
| 2023 | 2023-12-31 | $2.9M | $475,000 | +19.33% |
| 2022 | 2022-12-31 | $2.5M | $2.2M | +987.17% |
| 2021 | 2021-12-31 | $226,000 | $203,000 | +882.61% |
| 2020 | 2020-12-31 | $23,000 | $9,000 | +64.29% |
| 2019 | 2019-12-31 | $14,000 | $4,210 | +43.00% |
| 2018 | 2018-12-31 | $9,790 | $2,680 | +37.69% |
| 2017 | 2017-12-31 | $7,110 | $3,317 | +87.45% |
| 2016 | 2016-12-31 | $3,793 | — | — |
PAVmed quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $19,000 | −$3,000 | −13.64% |
| Q1 2026 | 2026-03-31 | $20,000 | −$23,000 | −53.49% |
| Q4 2025 | 2025-12-31 | $18,000 | — | — |
| Q3 2025 | 2025-09-30 | $22,000 | −$216,000 | −90.76% |
| Q2 2025 | 2025-06-30 | $22,000 | −$283,000 | −92.79% |
| Q1 2025 | 2025-03-31 | $43,000 | −$543,000 | −92.66% |
| Q3 2024 | 2024-09-30 | $238,000 | −$495,000 | −67.53% |
| Q2 2024 | 2024-06-30 | $305,000 | −$442,000 | −59.17% |
| Q1 2024 | 2024-03-31 | $586,000 | −$141,000 | −19.39% |
| Q3 2023 | 2023-09-30 | $733,000 | $33,000 | +4.71% |
| Q2 2023 | 2023-06-30 | $747,000 | −$68,000 | −8.34% |
| Q1 2023 | 2023-03-31 | $727,000 | $511,000 | +236.57% |
| Q3 2022 | 2022-09-30 | $700,000 | $668,000 | +2087.50% |
| Q2 2022 | 2022-06-30 | $815,000 | $799,000 | +4993.75% |
| Q1 2022 | 2022-03-31 | $216,000 | $204,000 | +1700.00% |
| Q3 2021 | 2021-09-30 | $32,000 | $24,000 | +300.00% |
| Q2 2021 | 2021-06-30 | $16,000 | $10,000 | +166.67% |
| Q1 2021 | 2021-03-31 | $12,000 | $9,000 | +300.00% |
| Q3 2020 | 2020-09-30 | $8,000 | $5,000 | +166.67% |
| Q2 2020 | 2020-06-30 | $6,000 | $2,719 | +82.87% |
| Q1 2020 | 2020-03-31 | $3,000 | $0 | 0.00% |
| Q3 2019 | 2019-09-30 | $3,000 | $361 | +13.68% |
| Q2 2019 | 2019-06-30 | $3,281 | $1,479 | +82.08% |
| Q1 2019 | 2019-03-31 | $3,000 | $1,197 | +66.39% |
| Q3 2018 | 2018-09-30 | $2,639 | −$3,605 | −57.74% |
| Q2 2018 | 2018-06-30 | $1,802 | −$1 | −0.06% |
| Q1 2018 | 2018-03-31 | $1,803 | $101 | +5.93% |
| Q3 2017 | 2017-09-30 | $6,244 | $4,766 | +322.46% |
| Q2 2017 | 2017-06-30 | $1,803 | $1,098 | +155.74% |
| Q1 2017 | 2017-03-31 | $1,702 | $1,570 | +1189.39% |
| Q3 2016 | 2016-09-30 | $1,478 | — | — |
| Q2 2016 | 2016-06-30 | $705 | — | — |
| Q1 2016 | 2016-03-31 | $132 | — | — |
PAVmed depreciation and amortization trends
Over the last five fiscal years, PAVmed's depreciation and amortization increased from $23,000 to $105,000, a change of $82,000. The latest reported quarter, Q2 2026, shows $19,000.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review PAVmed source filings ↗